---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-135207"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:47:02.519604+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports RLY-2608+fulvestrant median PFS 11.4 months in 2L breast cancer; plans pivotal study in 2025

## Summary
- Median PFS 9.2 months overall, 11.4 months in 2L patients at RP2D (600mg BID) without PTEN/AKT co-mutations.
- Confirmed ORR 39% overall, 67% in kinase-mutation patients; CBR 67%; median follow-up 9.5 months.
- Low discontinuation rate (2 patients due to TRAEs); 94% median dose intensity; only 3% Grade 3 hyperglycemia.
- Cash and investments ~$840M as of Q3 2024; funds 2L pivotal study planned for 2025.
- Triplet combinations with ribociclib (ongoing) and atirmociclib (initiated) progressing; VMs study in Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-135207
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024135207/0000950170-24-135207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024135207/rlay-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-135207
- JSON: https://secwatch.observer/filing/0000950170-24-135207.json
- Plain text: https://secwatch.observer/filing/0000950170-24-135207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.